Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details Narrative)

SUBSEQUENT EVENTS (Details Narrative) ₩ in Millions	1 Months Ended
SUBSEQUENT EVENTS (Details Narrative) ₩ in Millions	May 31, 2024 USD ($)	Apr. 30, 2024 KRW (₩)	Apr. 30, 2024 USD ($)	Nov. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Jul. 31, 2023 USD ($)	May 31, 2023 USD ($)	Apr. 30, 2023 KRW (₩)	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Apr. 30, 2024 USD ($)	Apr. 30, 2023 USD ($)
Revenue Purchase Agreement [Member]
Subsequent Event [Line Items]
Sale of accounts receivable				$ 762,200	$ 1,377,500	$ 828,000	$ 528,200			$ 700,212
Proceeds from sale of notes receivable				468,650	875,000	300,000	368,600			$ 491,933
Amount agreed to pay weekly sales receipts until future receipt is delivered				$ 49,000	$ 81,000	$ 26,000	$ 19,000
Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member]
Subsequent Event [Line Items]
Offset amount against principal amount of convertible bond								₩ 2,900				$ 2,200,000
Cash proceeds to shortfall in revenue and profits								₩ 307	$ 236,000
Subsequent Event [Member] \| Revenue Purchase Agreement [Member]
Subsequent Event [Line Items]
Sale of accounts receivable	$ 1,628,000
Proceeds from sale of notes receivable	1,001,000
Amount agreed to pay weekly sales receipts until future receipt is delivered	$ 58,143
Subsequent Event [Member] \| Telcon RF Pharmaceuticals, Inc. ("Telcon") [Member] \| API Supply Agreement [Member]
Subsequent Event [Line Items]
Offset amount against principal amount of convertible bond		₩ 3,500									$ 2,500,000
Cash proceeds to shortfall in revenue and profits		₩ 893	$ 640,000